Affymax, Inc. (AFFY)
OTCMKTS · Delayed Price · Currency is USD
0.0416
+0.0399 (2,347.06%)
At close: Oct 9, 2026
Affymax Revenue
Affymax had revenue of $42.00K in the quarter ending June 30, 2014, a decrease of -92.00%. This brings the company's revenue in the last twelve months to $42.00K, down -99.86% year-over-year. In the year 2013, Affymax had annual revenue of $1.37M, down -98.55%. That makes Affymax the 46,634th largest company in the world by revenue and 6,990th in the United States.
Revenue (ttm)
42.00K
Revenue Growth
-99.86%
P/S Ratio
73.78
Revenue / Employee
21.00K
Employees
2
Market Cap
3.10M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2013 | 1.37M | -93.00M | -98.55% |
| Dec 31, 2012 | 94.37M | 46.65M | 97.76% |
| Dec 31, 2011 | 47.72M | -64.80M | -57.59% |
| Dec 31, 2010 | 112.52M | -2.38M | -2.07% |
| Dec 31, 2009 | 114.90M | 32.05M | 38.68% |
| Dec 31, 2008 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2007 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2006 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2005 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2004 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Emmaus Life Sciences | 15.53M |
| International Stem Cell | 9.51M |
| BioAtla | 8.50M |
| Pacific Software | 2.40M |
| Vaccinex | 601.00K |
| GPL Holdings | 376.54K |
| Enzolytics | 46.59K |